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Sulfonylurea Drugs and
Cardiovascular Mortality
The study by Garratt et al. (1) emphasizes an important concept
that is emerging from the cumulative published data: sulfonylurea
agents worsen cardiovascular risks in type 2 diabetes. This study
documented a higher mortality among diabetic patients treated by
direct angioplasty who received sulfonylurea drugs as compared
with those who did not.
In a recent study from our institution published in the European
Heart Journal (2), we documented similar adverse effects of
sulfonylurea therapy after elective coronary angioplasty. This
comprehensive risk-adjusted study involved ;16,000 patients and
showed that sulfonylurea therapy exerted an independent adverse
outcome after angioplasty and accounted for much of the long-
term survival advantage for bypass surgery over angioplasty in
diabetic patients.
For three decades, data have been accumulating suggesting
potential adverse effects of sulfonylurea therapy on large-vessel
atherosclerotic vascular disease (3). These agents improve glucose
control by increasing insulin levels. Increased insulin levels have
independent adverse effects in both diabetic and nondiabetic
patients, possibly by increasing atherogenesis and cardiovascular
events. Furthermore, sulfonylurea agents cause vasoconstriction
and block the adenosine triphosphate-sensitive potassium (KATP)
channels not only in the pancreas but also in the cardiac cells and
coronary vasculature. This impairs ischemic preconditioning and
may predispose to larger infarctions and dangerous arrhythmias.
The recently published United Kingdom Perspective Diabetes
Study (UKPDS) (4) documented improved survival with met-
formin as compared with sulfonylurea agents in overweight type 2
diabetic patients. These cumulative data should caution us against
the use of sulfonylurea agents as first-line therapy for diabetic
patients with coronary artery disease. The use of alternative oral
agents is both logical and feasible with the availability of met-
formin, troglitazone, rosiglitazone, and orlistat, all of which
improve diabetes by improving insulin sensitivity (rather than
raising insulin levels).
Approximately four of five diabetic patients die of cardiovascular
causes, irrespective of whether or not atherosclerotic disease is
present at baseline (3). Although we often relegate the medical
management of diabetes to endocrinologists and primary care
physicians, cardiologists should ensure that the therapies that have
been shown to improve cardiovascular prognosis (e.g., aspirin,
statins, angiotensin-converting enzyme inhibitors) are used when
indicated, and agents like sulfonylureas, which may increase
cardiovascular risk, are avoided when possible.
James H. O’Keefe, Jr., MD
Ben D. McCallister, MD
Eugene H. Blackstone, MD
Cardiovascular Consultants, P.C.
Kansas City, Missouri
PII S0735-1097(99)00284-3
REFERENCES
1. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes
DR, Jr. Sulfonylurea drugs increase early mortality in patients with
diabetes mellitus after direct angioplasty for acute myocardial infarction.
J Am Coll Cardiol 1999;33:119–24.
2. O’Keefe JH, Blackstone EH, Sergeant P, McCallister BD. The optimal
mode of coronary revascularization for diabetics. Eur Heart J 1998;19:
1696–703.
3. O’Keefe, Jr. JH, Miles JM, Harris WH, Moe RM, McCallister B.
Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo
Clin Proc 1999;74:171–80.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive
blood-glucose control with metformin on complications in overweight
patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854.
958 Letters to the Editor JACC Vol. 34, No. 3, 1999
September 1999:949–58
